Please note that this content was created in 2018. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This is a recording of a session from the AMP 2018 Annual Meeting & Expo. Purchase the entire AMP Annual Meeting & Expo 2018 Recordings for a significant discount!
For mature T-cell lymphomas, the recent application of genomic technologies has identified recurrent genetic alterations and enhanced our understanding of the pathogenetic mechanisms underlying this poorly understood category of non-Hodgkin lymphomas. Dr. Lim will discuss the potential relevance of these findings to diagnosis, prognosis, and therapy. Targeted small molecule therapeutics have transformed the therapy of chronic lymphocytic leukemia (CLL). While most patients achieve durable remissions, many with high genomic risk disease will relapse, and their outcomes are poor. Dr. Woyach will discuss known and suspected mechanisms of resistance to targeted therapies as well as pathways and agents with the potential to prevent or treat resistant disease.
Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, The Ohio State University, Columbus, OH, USA
Towards a Genomic Classification of T Cell Malignancies: Opportunities for Precision Medicine
Megan S. Lim, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA
Objectives:
- Summarize the genetic diversity of mature T-cell malignancies to improve diagnosis and discover opportunities for tailored therapy.
- Discuss targeted therapy for chronic lymphocytic leukemia (CLL), mechanisms of resistance to these therapies, especially Bruton tyrosine kinase (BTK) inhibitors.
- Describe novel therapies with the potential to overcome resistance to BTK inhibitors.
Duration: 1.50 hr
Recording Date: November 3, 2018
Last day to purchase: December 31, 2021
There are no CME/CMLE or SAMs credits available.Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
